Related references
Note: Only part of the references are listed.Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma
Lin Zhou et al.
FRONTIERS IN PHARMACOLOGY (2022)
Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research
Xianbo Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Medication Adherence in Patients With Glaucoma and Disability
Chiun-Ho Hou et al.
JAMA OPHTHALMOLOGY (2021)
Moving Pharmacogenetics Into Practice: It's All About the Evidence!
Jasmine A. Luzum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics
Heng-Yi Wu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Editorial: Pharmacogenetics Research and Clinical Applications: An International Landscape of the Accomplishments, Challenges, and Opportunities
Nathalie K. Zgheib et al.
FRONTIERS IN PHARMACOLOGY (2020)
Primary Open-Angle Glaucoma Preferred Practice Pattern®
Steven J. Gedde et al.
OPHTHALMOLOGY (2020)
Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma
Peter G. Klimko et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients A meta-analysis
Wenquan Tang et al.
MEDICINE (2019)
Correlations of AFAP1, GMDS and PTGFR gene polymorphisms with intra-ocular pressure response to latanoprost in patients with primary open-angle glaucoma
X. -J. Cui et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Prostaglandins in the eye: Function, expression, and roles in glaucoma
Lance P. Doucette et al.
OPHTHALMIC GENETICS (2017)
PTGFR and SLCO2A1 Gene Polymorphisms Determine Intraocular Pressure Response to Latanoprost in Han Chinese Patients with Glaucoma
Pu Zhang et al.
CURRENT EYE RESEARCH (2016)
Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics (vol 10, e0136632, 2015)
Luca Rossetti et al.
PLOS ONE (2016)
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
David F. Garway-Heath et al.
LANCET (2015)
Association between SNPs of Metalloproteinases and Prostaglandin F2α Receptor Genes and Latanoprost Response in Open-Angle Glaucoma
Fernando Ussa et al.
OPHTHALMOLOGY (2015)
Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients
Li-chen Gao et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension
Mayumi Sakurai et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Applications of CYP450 Testing in the Clinical Setting
C. F. Samer et al.
MOLECULAR DIAGNOSIS & THERAPY (2013)
Glaucoma: Present Challenges and Future Trends
Paolo Bettin et al.
OPHTHALMIC RESEARCH (2013)
Lack of association between polymorphisms in the prostaglandin F2a receptor and solute carrier organic anion transporter family 2A1 genes and intraocular pressure response to prostaglandin analogs
Catherine A. McCarty et al.
OPHTHALMIC GENETICS (2012)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Effects of Selective Serotonin Reuptake Inhibitors on Timolol Metabolism in Human Liver Microsomes and Cryo-Preserved Hepatocytes
Marjo Volotinen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2010)
Association of CYP2D6 Single-Nucleotide Polymorphism with Response to Ophthalmic Timolol in Primary Open-Angle Glaucoma-A Pilot Study
Hongzhi Yuan et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
Intraocular pressure response to topical β-blockers associated with an ADRB2 single-nucleotide polymorphism
Catherine A. McCarty et al.
ARCHIVES OF OPHTHALMOLOGY (2008)
Canadian glaucoma study - 2. Risk factors for the progression of open-angle glaucoma
Balwantray C. Chauhan et al.
ARCHIVES OF OPHTHALMOLOGY (2008)
Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes
Y. Liang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Pharmacogenetics of ophthalmic topical β-blockers
Duska J. Sidjanin et al.
PERSONALIZED MEDICINE (2008)
An evaluation of the rate of nonresponders to latanoprost therapy
Luca Rossetti et al.
JOURNAL OF GLAUCOMA (2006)
Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol.: A pilot study
T Nieminen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients
AGP Konstas et al.
OPHTHALMOLOGY (2005)
The advanced glaucoma intervention study (AGIS) - 13. Comparison of treatment outcomes within race: 10-year results
F Ederer et al.
OPHTHALMOLOGY (2004)
A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure
N Choplin et al.
SURVEY OF OPHTHALMOLOGY (2004)
Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma
CB Camras et al.
JOURNAL OF GLAUCOMA (2003)
A retrospective review of non-responders to latanoprost
WJ Scherer
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2002)
Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype:: a role for the CYP2D6*35 allele in ultrarapid metabolism?
R Lovlie et al.
PHARMACOGENETICS (2001)
Share Paper
